We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serological Markers of RA Determined in Patients with aβ2GPI-IgA

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: The gold standard for the determination of antinuclear antibodies (ANA) is the indirect immunofluorescence test (IIFT) with human epithelial cells (HEp-2), which is known for its high sensitivity and specificity (Photo courtesy of Euroimmun)
Image: The gold standard for the determination of antinuclear antibodies (ANA) is the indirect immunofluorescence test (IIFT) with human epithelial cells (HEp-2), which is known for its high sensitivity and specificity (Photo courtesy of Euroimmun)

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease. It is characterized by synovial inflammation that can lead to irreversible joint damage and disability when not managed. Biomarkers of RA available for routine clinical use are rheumatoid factors (RF) and anti-cyclic citrullinated peptides (CCP-Ab).

Beta 2 Glycoprotein I (β2GPI) is a plasma protein and plays a key role in hemostasis, homeostasis, and immunity. Antibodies against β2GPI (aβ2GPI) have been associated with antiphospholipid syndrome (APS) pathogenicity. Common links between RA and APS have been reported. Glycosylation is implicated in the synthesis of highly pathogenic forms of antibodies to citrullinated proteins. Moreover, dysregulation of glycosylation could also generate antibodies of APS.

Immunologists at the Farhat-Hached University Hospital (Sousse, Tunisia) conducted a retrospective study that included sera of 67 patients with anti-β2 glycoprotein I antibodies (aβ2GPI) of IgA isotype. Ninety healthy blood donors (HBD) were used as a control group. The serum samples were evaluated for aCL-IgG, IgA, and IgM using a commercial enzyme-linked immunosorbent assay (ELISA; Orgentec Diagnostika, Mainz, Germany). Results were expressed as arbitrary units with a cutoff for positivity of 10 U/mL for IgA and IgG and 7 U/mL for IgM.

The determination of aβ2GPI IgG, IgA, and IgM was carried out with an Orgentec Diagnostika commercial ELISA, using a purified human β2GPI. The results were expressed as arbitrary units with a cutoff for positivity of 8 U/mL. Antinuclear antibodies screening was performed by the indirect immunofluorescence technique using human epithelial type 2 (HEp-2) as a substrate (Euroimmun, Hamburg, Germany). Detection of ANA at a dilution superior to or equal to 1:80 was considered a positive result.

The scientists reported that 17 patients and eight HBD had CCP-Ab and/or RF (25.4% versus 8.9%, odds ratio = 3.5). The frequency of CCP-Ab was significantly higher in patients than in healthy subjects (14.9% versus 3.3%). IgA isotype of RF was significantly higher in patients than in controls (7.5% versus 0%). In male patients, CCP-Ab and/or RF were more frequent than in healthy male subjects (37.5% versus 11.8%). In patients, no correlation was found between the levels of aβ2GPI-IgA and CCP-Ab. There was no correlation between the level aβ2GPI-IgA and the level of the isotypes of RF (IgG, IgA, and IgM).

The authors concluded that a high frequency of autoantibodies of RA in patients with aβ2GPI-IgA, suggesting that these patients could be at higher risk of developing RA. Following the clinical features and serological markers of these patients over the years could confirm this data. The study was published on June 6, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Farhat-Hached University Hospital
Orgentec Diagnostika 
Euroimmun 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more